Non–high-density lipoprotein cholesterol target achievement in patients on lipid-lowering drugs and stratified by triglyceride levels in the Arabian Gulf

Slides:

Advertisements

Similar presentations

© Copyright 2009 by the American Association for Clinical Chemistry Nonfasting Lipids, Lipoproteins, and Apolipoproteins in Individuals With and Without.

Advertisements

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels Michael H. Davidson, MD Journal of Clinical.

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera,

Lipid abnormalities in foreign-born and US-born patients in a medical group Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Low-Density Lipoprotein Cholesterol, Non–High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients.

Copyright © 2012 American Medical Association. All rights reserved.

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Martin W. Schoen, MD, MPH, Joanne Salas, MPH, Jeffrey F

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Rounding numbers The Journal of Thoracic and Cardiovascular Surgery

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men Gloria Lena Vega, PhD, Scott M. Grundy,

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial Erik S.G. Stroes, MD, PhD, Andrey.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report Terry A. Jacobson, MD, Matthew K. Ito,

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera,

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

J. W. Balder, MD, PhD, P. J. Lansberg, MD, PhD, M. H. Hof, MSc, A

Genetic epidemiology of autosomal recessive hypercholesterolemia in Sicily: Identification by next-generation sequencing of a new kindred Rossella Spina,

Meredith Kilgore, PhD, Paul Muntner, PhD, J

II. assessment of dyslipidemias

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

Lysosomal acid lipase deficiency: A hidden disease among cohorts of familial hypercholesterolemia? Joana Rita Chora, MSc, Ana Catarina Alves, PhD, Ana.

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial James D. Otvos,

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1 Omar Abdel-Razek, MD, Singh N.

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.

Task-sharing interventions for cardiovascular risk reduction and lipid outcomes in low- and middle-income countries: A systematic review and meta-analysis

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Sudhir K. Unni, PhD, MBA, Ruben G.W.

Extended-Release Niacin/Laropiprant Lowers Serum Phosphorus Concentrations in Patients with Type 2 Diabetes and Mild Hyperphosphatemia Andrew G. Bostom,

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

Xing Wu, MD, PhD, Zhexin Yu, MD, MS, Wen Su, MD, PhD, Daniel A

The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis Moritz C. Wyler von Ballmoos, MD, MPH, Bernhard.

Khurram Nasir et al. JACC 2015;66:

Optimal high-density lipoprotein cholesterol cutoff for predicting cardiovascular disease: Comparison of the Korean and US National Health and Nutrition.

Per-Ola Attman, M.D, Petar Alaupovic, Ola Samuelsson

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia Raul D. Santos, Frederick J. Raal,

Sokunthea Peou, PharmD, Brittany Milliard-Hasting, MD, Sachin A

Familial hypercholesterolemia in a European Mediterranean population—Prevalence and clinical data from 2.5 million primary care patients Alberto Zamora,

Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical.

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

Rhanderson Cardoso, MD, Roger S

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

Volume 67, Issue 4, Pages (April 2005)

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Dean G. Karalis, MD Mayo Clinic Proceedings

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results.

Can Low-Radiation Coronary Computed Tomography Angiography Improve Upon Clinical Risk Assessment in Patients with Familial Hypercholesterolemia?* Anna.

Urbanization, mainly rurality, but not altitude is associated with dyslipidemia profiles Maria Lazo-Porras, Antonio Bernabe-Ortiz, Renato Quispe, German.

III. Treating dyslipidemias

Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia Frederick J. Raal, PhD, Marjet J. Braamskamp,

Prediction of Cardiovascular Disease Events by Lipoprotein(a) According to LDL-C in Older High Risk Adults Nathan D. Wong, PhD, Shravanthi R. Gandra,

PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies.

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design Dirk J. Blom, MD, PhD, Zahi A. Fayad,

Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia Anna.

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Presentation transcript:

Non–high-density lipoprotein cholesterol target achievement in patients on lipid-lowering drugs and stratified by triglyceride levels in the Arabian Gulf Khamis Al-Hashmi, MD, PhD, Ibrahim Al-Zakwani, PhD, Wael Al Mahmeed, MD, Mohammed Arafah, MD, Ali T. Al-Hinai, MD, Abdullah Shehab, MD, Omer Al Tamimi, MD, Mahmoud Al Awadhi, MD, Shorook Al Herz, MD, Faisal Al Anazi, MD, Khalid Al Nemer, MD, Othman Metwally, MD, Akram Alkhadra, MD, Mohammed Fakhry, MD, Hossam Elghetany, MD, Abdel Razak Medani, MD, Afzal Hussein Yusufali, MD, Obaid Al Jassim, MD, Omar Al Hallaq, MD, Fahad Omar Ahmed S. Baslaib, MD, Haitham Amin, MD, Raul D. Santos, MD, PhD, Khalid Al-Waili, MD, Khalid Al-Rasadi, MD Journal of Clinical Lipidology Volume 10, Issue 2, Pages 368-377 (March 2016) DOI: 10.1016/j.jacl.2015.12.021 Copyright © 2016 National Lipid Association Terms and Conditions

Figure 1 Lipid target achievements (LDL-C, non–HDL-C, and Apo B) in very high atherosclerotic cardiovascular disease (ASCVD)–risk patients stratified by triglyceride levels (N = 3425). Therapeutic lipoprotein targets for the very high ASCVD risk group were LDL-C <70 mg/dL (<1.8 mmol/L), Apo B <80 mg/dL (<0.80 g/L), and non–HDL-C <100 mg/dL (<2.6 mmol/L). Apo, apolipoprotein; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein. Journal of Clinical Lipidology 2016 10, 368-377DOI: (10.1016/j.jacl.2015.12.021) Copyright © 2016 National Lipid Association Terms and Conditions

Figure 2 Lipid target achievements (LDL-C, non–HDL-C, and Apo B) in high atherosclerotic cardiovascular disease (ASCVD)–risk patients stratified by triglyceride levels (N = 958). Therapeutic lipoprotein targets for the high ASCVD risk group were LDL-C <100 mg/dL (2.6 mmol/L), Apo B <90 mg/dL (0.90 g/L), and non–HDL-C <130 mg/dL (3.3 mmol/L). Apo, apolipoprotein; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein. Journal of Clinical Lipidology 2016 10, 368-377DOI: (10.1016/j.jacl.2015.12.021) Copyright © 2016 National Lipid Association Terms and Conditions

Figure 3 Prevalence of low HDL-C in very high and high atherosclerotic cardiovascular disease (ASCVD)–risk patients and controlled non–HDL-C stratified by triglyceride levels (N = 1809). Despite the lack of a recommended HDL-C goal by guidelines, satisfactory HDL-C was defined as <40 mg/dL (<1.03 mmol/L) for males or <50 mg/dL (<1.29 mmol/L) for females. Therapeutic non–HDL-C targets for high and very high ASCVD risk patients were <130 mg/dL (<3.3 mmol/L) and <100 mg/dL (<2.6 mmol/L), respectively. Apo, apolipoprotein; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein. Journal of Clinical Lipidology 2016 10, 368-377DOI: (10.1016/j.jacl.2015.12.021) Copyright © 2016 National Lipid Association Terms and Conditions

Figure 4 Lipid target achievements (LDL-C, non–HDL-C, and Apo B) in diabetic patients stratified by triglyceride levels (N = 2755). Therapeutic lipoprotein targets for the high atherosclerotic cardiovascular disease (ASCVD)–risk group were LDL-C <100 mg/dL (2.6 mmol/L), non–HDL-C <130 mg/dL (3.3 mmol/L), and Apo B <90 mg/dL (0.90 g/L). Therapeutic lipoprotein targets for the very high ASCVD risk group were LDL-C <70 mg/dL (<1.8 mmol/L), non–HDL-C <100 mg/dL (<2.6 mmol/L), and Apo B <80 mg/dL (<0.80 g/L). Apo, apolipoprotein; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein. Journal of Clinical Lipidology 2016 10, 368-377DOI: (10.1016/j.jacl.2015.12.021) Copyright © 2016 National Lipid Association Terms and Conditions

Figure 5 Lipid target achievements (LDL-C, non–HDL-C, and Apo B) in nondiabetic patients stratified by triglyceride levels (N = 670). Therapeutic lipoprotein targets for the high atherosclerotic cardiovascular disease (ASCVD)–risk group were LDL-C <100 mg/dL (2.6 mmol/L), non–HDL-C <130 mg/dL (3.3 mmol/L), and Apo B <90 mg/dL (0.90 g/L). Therapeutic lipoprotein targets for the very high ASCVD risk group were LDL-C <70 mg/dL (<1.8 mmol/L), non–HDL-C <100 mg/dL (<2.6 mmol/L), and Apo B <80 mg/dL (<0.80 g/L). Apo, apolipoprotein; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein. Journal of Clinical Lipidology 2016 10, 368-377DOI: (10.1016/j.jacl.2015.12.021) Copyright © 2016 National Lipid Association Terms and Conditions